(Q34548647)

2 August 2017

1 reference

title

The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents (English)

1 reference

2 August 2017

1 reference

Christoph Rosak

1

1 reference

2 August 2017

publication date

1 January 2002

1 reference

Journal of Diabetes and its Complications

2 August 2017

published in

1 reference

2 August 2017

volume

16

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

123-132

1 reference

Mechanisms of the glycaemic effects of sulfonylureas

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

1 reference

7 January 2021

Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

The sulfonylurea controversy: more questions from the heart

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Miglitol: assessment of its role in the treatment of patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Insulin release from isolated, human islets after acute or prolonged exposure to glimepiride

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Clinical profile of glimepiride

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Direct effects of glimepiride on protein expression of cardiac glucose transporters

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Recent developments and emerging therapies for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Repaglinide and related hypoglycemic benzoic acid derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

The sulfonylurea glimepiride regulates intracellular routing of the insulin-receptor complexes through their interaction with specific protein kinase C isoforms.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Reducing the burden of diabetes: managing cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Meglitinide analogues in the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Glimepiride. A review of its use in the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Drug therapy of postprandial hyperglycaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Imitating mickey mouse can be dangerous

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

The effect of the timing and the administration of acarbose on postprandial hyperglycaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Differentiation and reversal of malignant changes in colon cancer through PPARgamma

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

An overview of the safety and tolerance of glimepiride

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Thiazolidinediones: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Miglitol, a new alpha-glucosidase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Current therapies and emerging targets for the treatment of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

Obesity and type 2 diabetes: a conflict of interests?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900207-0

7 January 2021

10.1016/S1056-8727(01)00207-0

Identifiers

DOI

1 reference

2 August 2017

1 reference